ヒトにおけるDMTの固定順序、非盲検、用量漸増研究
The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.
調査の概要
詳細な説明
The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Hamideh Safi-Aghdam, MD
- 電話番号:4650 203-932-5711
- メール:hamideh.safi-aghdam@yale.edu
研究場所
-
-
Connecticut
-
West Haven、Connecticut、アメリカ、06516
- 募集
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
-
主任研究者:
- Deepak C D'Souza, MD
-
コンタクト:
- Schizophrenia Research Clinic
- 電話番号:4525 203-932-5711
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Healthy controls inclusion criteria:
- Medically healthy
- Psychiatrically healthy
Healthy controls exclusion criteria:
- Unstable medical conditions
- Psychiatric illness
Depression inclusion criteria:
- Medically healthy
- Diagnosis of major depressive disorder
Depression exclusion criteria:
-Unstable medical conditions
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:非ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:0.1 mg/kg DMT
0.1 mg/kg DMT administered intravenously |
0.1 mg/kg DMT
他の名前:
|
|
アクティブコンパレータ:0.3 mg/kg DMT
0.3 mg/kg DMT administered intravenously |
0.3 mg/kg DMT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Blood Pressure
時間枠:-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
|
Systolic and diastolic blood pressure will be measured before and several times after the administration of DMT on each test day. |
-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
|
|
Change in Heart Rate
時間枠:-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
|
Heart rate will be measured before and several times after the administration of DMT on each test day. |
-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration
|
|
Change in Psychedelic Effects
時間枠:-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
|
The modified Altered States of Consciousness Rating Scale (ASC) will be used to assess drug-induced altered states of consciousness before and several times after drug administration. This is a 23-item subjective rating scale that will be completed using a visual analog scale format. Questions are scored 0 to 100 each; higher numbers indicate greater psychedelic effects. |
-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
|
|
Change in Anxiety
時間枠:-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
|
Anxiety will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the net anxiety produced by DMT. This will be collected before and several times after DMT administration. |
-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration
|
|
Drug Reinforcing Effects
時間枠:+120 minutes after DMT administration
|
Subjects will be asked to answer questions such as (1) How likely are you to use this drug? and (2) How much are you willing to pay for this experience? using a visual analog scale. |
+120 minutes after DMT administration
|
|
Overall Tolerability assessed by the VAS
時間枠:+120 minutes after DMT administration
|
Overall tolerability will be assessed using a visual analog scale that subjects will be asked to score from 0 (well tolerated) to 100 (intolerable) to capture the net tolerability of DMT. |
+120 minutes after DMT administration
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2000027720
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。